Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

FDA Expands TAVR Indication to Low-Risk Patients

Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization...
solaci -
Learn More
Structural heart disease

Loss in Life Expectancy after Surgical Aortic Valve Replacement

This study found after surgical aortic valve replacement (SAVR) patients had shorter life expectancy, compared against the...
solaci -
Learn More
Structural heart disease

Clinical Implications of the New Hypertension Guidelines

Hypertension is the first modifiable risk factor affecting morbidity and mortality in nearly half of the adults...
solaci -
Learn More
Mitral valve

New Promising Alternatives for Mitral Regurgitation

PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with...
solaci -
Learn More
Structural heart disease

Next-Day Discharge after TAVR: Equally Safe for All Prosthesis?

Yet scarce, there is evidence supporting next-day discharge (NDD) after TAVR is safe when patients receiving balloon...
solaci -
Learn More
Structural heart disease

Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Degenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent...
solaci -
Learn More
Structural heart disease

Pulmonary Hypertension: No Reason for TAVR Contraindication

In most severe aortic stenosis patients with pulmonary hypertension, transcatheter aortic valve replacement (TAVR) reduced pulmonary systolic...
solaci -
Learn More
Structural heart disease

Low-Risk TAVR Trending in All Papers

Transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe aortic stenosis appears to be safe...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy